Get the Stockscreener App
7.30
2.67%
0.19
After Hours:
7.70
0.40
+5.48%
Capricor Therapeutics Inc stock is traded at $7.30, with a volume of 4.66M.
It is up +2.67% in the last 24 hours and down -21.42% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$7.11
Open:
$7.25
24h Volume:
4.66M
Relative Volume:
2.71
Market Cap:
$333.44M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-8.7952
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
+0.00%
1M Performance:
-21.42%
6M Performance:
-56.83%
1Y Performance:
+34.19%
1-Day Range:
$7.12
$7.90
1-Week Range:
$6.27
$7.90
52-Week Range:
$3.52
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.30 | 333.44M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics Inc (CAPR) Q1 2025 Earnings Call Highlight - GuruFocus
Capricor Therapeutics Reports Q1 2025 Financial Results - TipRanks
Capricor: Q1 Earnings Snapshot - The Washington Post
Capricor Therapeutics (CAPR) Highlights Deramiocel Progress in Q - GuruFocus
Earnings call transcript: Capricor Therapeutics Q1 2025 reports wider loss, stock rises - Investing.com Australia
Capricor (CAPR) On Track for Duchenne Cardiomyopathy Therapy App - GuruFocus
Capricor Therapeutics reports Q1 EPS (53c), consensus (32c) - TipRanks
Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics Reports First Quarter 2025 Financial Results And Provides Corporate Update - marketscreener.com
Capricor Therapeutics (CAPR) Sees Elevated Option Activity Ahead of Earnings | CAPR Stock News - GuruFocus
CAPR STOCK ALERT: Levi & Korsinsky Notifies Capricor Therapeutics, Inc. Investors of an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Anticipates Q1 Earnings Report - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor - Bluefield Daily Telegraph
Capricor Therapeutics (CAPR) Appoints New Chief Medical Officer - GuruFocus
Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer - The Manila Times
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. Investors of the Ongoing Investigation Into Potential Violations of Securities LawsCAPR - ACCESS Newswire
What To Expect From Capricor Therapeutics Inc (CAPR) Q1 2025 Ear - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
A Look Ahead: Capricor Therapeutics's Earnings Forecast - Nasdaq
ATTENTION CAPR SHAREHOLDERS: Investors Who Lost Money on Capricor Therapeutics, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation - ACCESS Newswire
Capricor Therapeutics (CAPR) Projected to Post Earnings on Tuesday - Defense World
CAPR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Capricor Therapeutics, Inc. - ACCESS Newswire
New FDA Leadership Could Raise The Bar For Drug Approvals - Benzinga
Shareholders that lost money on Capricor Therapeutics, Inc. (CAPR) should contact Levi & Korsinsky about Securities Fraud InvestigationCAPR - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cable One, Inc. - GlobeNewswire Inc.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet - simplywall.st
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire
MetLife Investment Management LLC Makes New Investment in Capricor Therapeutics Inc (NASDAQ:CAPR) - Defense World
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How the (CAPR) price action is used to our Advantage - news.stocktradersdaily.com
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation - Benzinga
Capricor falls 12% as FDA orders panel to discuss Duchenne cardiomyopathy asset - MSN
Capricor Therapeutics to Present First Quarter 2025 Financial Re - GuruFocus
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 | CAPR Stock News - GuruFocus
Capricor Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on May 13 - Nasdaq
Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13 - GlobeNewswire
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duch - GuruFocus
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting for Duchenne Treatment | CAPR Stock News - GuruFocus
FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy - Endpoints News
US FDA to convene expert panel for Capricor Therapeutics' DMD cell therapy - Reuters
Sector Update: Health Care Stocks Lower Monday Afternoon - marketscreener.com
Capricor Therapeutics (CAPR) Faces FDA Advisory Meeting, Shares Drop - GuruFocus
Capricor Therapeutics Shares Fall as FDA Plans Panel Review for Duchenne Treatment - marketscreener.com
Capricor Share Slide 12% as FDA Calls Advisory Panel for Duchenne Cardiomyopathy Therapy - paginasiete.bo
Capricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s Optimistic - Asianet Newsable
Capricor falls after FDA to hold advisory meeting for cell therapy - TradingView
Capricor Therapeutics (CAPR) Anticipates Positive FDA Review Despite Stock Dip | CAPR Stock News - GuruFocus
CAPR: Capricor Therapeutics Advances FDA Review for Deramiocel | CAPR Stock News - GuruFocus
Capricor Therapeutics Announces Completion of Mid-Cycle - GlobeNewswire
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):